As a Free StocksGuide user, you can view scores for all 7,030 stocks worldwide.
6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:
6 Analysts have issued a Virpax Pharmaceuticals Inc forecast:
| Dec '24 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | - - |
-
|
|
| EBIT (Operating Income) EBIT | -12 -12 |
23%
23%
|
|
| Net Profit | -12 -12 |
21%
21%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Virpax Pharmaceuticals, Inc. is a preclinical stage biopharmaceutical company, which engages in the development of branded, non-addictive pain management products. Its products include metered-dose spray, liposomal gel encapsulates, and intranasal spray. The company was founded by Anthony P. Mack and Jeffrey A. Gudin in 2016 and and is headquartered in Berwyn, PA.
| Head office | United States |
| CEO | Jay Dhaliwal |
| Employees | 2 |
| Founded | 2016 |
| Website | virpaxpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


